Market closed· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Immunovia AB (LTS:0G8X) reports strong commercial adoption with 27 high-risk surveillance programs using PancreaSure, while managing cash burn below guidance ahead of Medicare submission.
Immunovia AB (IMMVF) outlines its strategic initiatives and financial hurdles as it advances the PancreaSure test and seeks broader market penetration.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.